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An intriguing and controversial issue in surgical treatment of
breast cancer is whether the timing of surgery in relation to the
menstrual cycle affects the long-term rates of disease recurrence
and survival. Several independent groups of researchers have
reported an increase of up to 300% in the 10-year mortality rate of
women undergoing surgery during days 2–14 of their menstrual
cycle (Badwe et al, 1991; Senie et al, 1991; Saad et al, 1994).
Other groups, however, have suggested that it is the perimenstrual
period that is characterized by a higher mortality rate (Hrushesky
et al, 1989), and several studies have failed to detect any relation-
ship between the two variables (for review see Lemon and
Rodriguez-Sierra, 1996). The considerable number of independent
studies observing such a relationship suggests that this clinical
phenomenon is authentic. However, this phenomenon may rely
upon as yet unknown perioperative routines or circumstances,
which invariably differ between hospitals.
Importantly, the increase in the rate of mortality was only
found in women with positive lymph nodes, was due to malignant
recurrence at remote locations, and occurred not before 3 years
following surgery (Lemon and Rodriguez-Sierra, 1996). Thus, we
suggest that the clinical phenomenon is related to metastatic devel-
opment that is induced perioperatively and is modulated by the
menstrual cycle during the perioperative period. Because the clin-
ical phenomenon was not related to the expression of receptors for
sex-steroid by the excised tumour (Lemon and Rodriguez-Sierra,
1996), it is not likely that it results from direct effects of sex
hormones on the malignant tissue. Rather, it seems likely to result
from alterations in host physiological mechanisms that affect
metastatic development (e.g., levels of angiogenesis or immune
competence).
Animal studies have indicated that natural killer cell activity
(NKA) is an important immune function controlling the metastatic
process (Brittenden et al, 1996), and clinical observations have
supported these findings (Whiteside and Herberman, 1995).
However, in order to suggest that alteration in NKA is a potential
mechanism underlying the clinical phenomenon, it must be shown
that the modulatory effects of the menstrual/oestrous cycle on
NKA only become significant during the perioperative period. The
menstrual cycle should have no significant effects on metastatic
development outside the context of surgery. Otherwise, the effects
of the specific menstrual phase on the day of surgery would be
masked by the continuous effects of menstrual cycles preceding
and following surgery.
A predominant effect of the menstrual phase during surgery
may be a result of increased risk or increased susceptibility to
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Summary Clinical observations suggest that the rate of metastatic development and long-term mortality following surgery in breast cancer
patients is influenced by the menstrual phase during which surgery is conducted. The menstrual cycle is known to modulate various
physiological responses and medical conditions that involve adrenergic mechanisms (e.g., asthma). Natural killer activity (NKA), an immune
function controlling metastasis, is suppressed following surgery, and in vitro by adrenaline. We therefore hypothesize that the clinical
observation may be partly attributable to surgery-induced adrenergic suppression of NK-dependent resistance to metastasis, a suppression
that depends on menstrual phase during surgery. To test this hypothesis in rats, 140 F344 females at different phases of their oestrous cycle
were injected with a β -adrenergic agonist, metaproterenol (MP) (0.4 or 0.8 mg kg–1, s.c.), or with vehicle, before i.v. inoculation with MADB106
tumour cells. This syngeneic mammary adenocarcinoma line metastasizes only to the lungs, and is highly sensitive to NKA. In a second
experiment, the suppression of NKA by MP was studied in vitro in blood drawn at different phases of the oestrous cycle (n = 36). Finally, the
effects of stress on the number and activity of NK cells were assessed along the oestrous cycle (n = 71). The findings indicate that the
suppressive effects of MP on resistance to metastasis and on NKA, are significantly greater during the oestrous phase characterized by high
oestradiol levels (D3/proestrus/oestrus). Similarly, NKA per cell was suppressed by stress only during this phase. In untreated animals, in
which inadvertent stress was minimized, no effects of the oestrous cycle on NKA or on resistance to metastasis were evident. These findings
indicate that the oestrous cycle modulates adrenergic suppression of NKA and of resistance to metastasis. The relevance of these findings to
the above clinical observation, as well as that of our related findings in women from a parallel study, is discussed. © 2000 Cancer Research
Campaign http://www.bjcancer.com
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tively to such increase in metastatic development. First, metastatic
development could be promoted by a drop in levels of angiostatic
agents due to the removal of the primary tumour, or initiated by the
release of tumour emboli into circulation owing to the physical
manipulation of the tumour during surgery. Second, immune
suppression induced by surgical stress could render the organism
susceptible to metastatic development that would otherwise have
been kept under control. Indeed, marked suppression of NKA
following surgical intervention is clinically well documented
(Pollock et al, 1992; Beitsch et al, 1994; Brittenden et al, 1996;
Shirakawa et al, 1998), and we have recently shown that such
suppression in rats markedly promotes metastatic development
(Ben-Eliyahu et al, 1999). Several studies have implicated sympa-
thetic activation in suppressing NKA (Irwin et al, 1990; Brenner et
al, 1992; Wu and Pruett, 1996; Ben-Eliyahu and Shakhar, 2000).
For example, it was recently reported that the peripheral infusion
of a β -adrenergic agonist suppressed NKA in rats, consequently
causing a 30-fold increase in metastasis of a mammary adeno-
carcinoma (Shakhar and Ben-Eliyahu, 1998).
In patients, the perioperative period is characterized by marked
sympathetic discharge. The activation of the sympathetic nervous
system is induced by emotional and physical stress, certain anaes-
thetics, surgical hypothermia, pain and other factors. This charac-
teristic of the perioperative period may contribute to the clinically
established postoperative suppression of NKA. Indeed, cate-
cholamines have been shown to suppress human NKA in vitro
(Hellstrand and Hermodsson, 1989; Whalen and Bankhurst,
1990). Importantly, physiological responses and medical condi-
tions that involve adrenergic mechanisms have been shown to be
modulated by the menstrual cycle. For example, stress-induced
increases in heart rate and blood pressure are more pronounced
during the luteal phase of the menstrual cycle (Manhem et al,
1996; Litschauer et al, 1998), as are asthma attacks (Tan et al,
1997).
Therefore, in the current study we sought to assess whether
adrenergic suppression of NKA and resistance to metastasis are
also modulated by the oestrous cycle, and whether the oestrous
cycle would fail to significantly affect NKA and resistance to
metastasis in the absence of sympathetic activation. Only if both of
these conditions are met, will it be possible to claim that the
menstrual cycle modulates the intensity of NK suppression by
catecholamines, and that this modulation may contribute to the
clinically observed effects of the menstrual cycle on metastatic
development following surgery. To this end, the effects of the
oestrous cycle on NKA and resistance to metastasis were assessed
both in the presence and in the absence of a β -adrenergic agonist.
Three different approaches were used, each employing F344
female rats at different phases of their oestrous cycle: a) in vivo
assessment of the metastatic efficacy of the MADB106 mammary
adenocarcinoma line, following the administration of a β -adren-
ergic agonist, or in its absence. The MADB106 tumour is highly
sensitive to NKA and metastasizes only to the lungs; b) ex-vivo
assessment of the effects of swim stress on NKA measured in
blood drawn following stress; and c) assessment of the in vitro
impact of a β -adrenergic agonist on NKA in blood drawn at
different phases of the oestrous cycle. Possible confounding
effects of the inadvertent release of endogenous catecholamines
were minimized by various measures.
METHODS
Animals
Fischer 344 (F344) female rats were purchased from Harlan
Laboratories (Jerusalem, Israel), housed 4 per cage with free
access to food and water, and kept under a 12:12 h light:dark
cycle. At the time experiments were conducted, animals were
14–16 weeks old.
Minimizing procedural stress and assessing vaginal
cellularity
Prior to all experiments, rats were acclimatized to the vivarium for
a minimum of 3 weeks. All experiments were conducted during
the light phase, in which rats are inactive and their sympathetic
tone is low. To reduce procedural stress, rats were habituated to the
experimental routines. Specifically, all rats were handled for 6
consecutive days in a procedure room adjusted to the vivarium,
and vaginal smears were taken starting from the fourth day.
Following these 6 days of habituation, daily vaginal smears were
obtained from all rats for 12 consecutive days during the first half
of the light phase. On the twelfth day, at the same time as taking
vaginal smears, the experimental procedures were conducted (i.e.,
metaproterenol/saline injection, blood withdrawal or tumour injec-
tion). Within a minute of the experimenter’s entering the vivarium,
the designated cage was moved into the procedure room, as per
routine, and all 4 rats were injected subcutaneously, or simultane-
ously anaesthetized with halothane for tumour injection or blood
withdrawal. Most commonly, all rats remained asleep when an
experimenter entered the vivarium, and did not wake up before
vaginal smears were taken or the experimental procedure initiated
(on the twelfth day). When rats were returned to the vivarium
following a procedure, they went back to sleep within less than
5 min. Following blood withdrawal, plasma was replaced with an
artificial medium as soon as possible, in order to limit in vitro
exposure of WBC to catecholamines that may have been released
to the circulation in the minute proceeding blood withdrawal 
(e.g., during the 30 s of inducing the halothane anaesthesia).
Determining the oestrous phase and duration of
exposure to oestradiol
The 12 vaginal smears taken from each rat were stained (Wright
stain, modified; Sigma Diagnostic WS 32) and analysed according
to their cellular composition. The length of the last oestrous cycle
in the experiment (either 4 or 5 days in the F344 rat), as well as the
phase within the oestrous cycle on the day of the experiment, were
determined according to the standard criteria described by Everett
(Everett, 1989). As we have recently reported (Ben-Eliyahu et al,
submitted), oestradiol levels start to increase during the light phase
of the second day of diestrus, further increase during the third day
of diestrus (which occurs only in 5-day cyclers), and reaches its
highest levels during the light phase of the following proestrus
day. On the following oestrus and diestrus-1 (metoestrus) days,
levels of oestradiol are at their lowest. Thus, the following nomi-
nation system was designed in order to reflect duration of prior
exposure to oestradiol, irrespective of the length of the oestrous
cycle. A mark of +1E (one complete day of prior exposure to
oestradiol – light phase to light phase) was given to 4-day cycler
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dioestrus, as levels of oestradiol started to increase 24 h earlier in
both cases. A mark of +2E was given to 4-day cyclers on oestrus
day, and 5-day cyclers on proestrus day, as levels of oestradiol
started to increase 48 h earlier in both cases. A mark of +3E was
given to 5-day cyclers on oestrus day, as levels of oestradiol started
to increase 72 h earlier. Although on the light phase of oestrus day,
the levels of oestradiol are already low, a + sign (+2 or +3) is given
because less than 24 h have elapsed since levels of oestradiol were
high. Exposure to low levels of oestradiol were marked as 1no.E
and 2no.E, indicating the lack of oestradiol exposure throughout
the last day or the last 2 days, respectively. In both 4- and 5-day
cyclers, dioestrus-1 (metoestrus) and dioestrus-2 were marked as
1no.E and 2no.E, respectively. In several figures and statistical
analyses, the oestrous cycle was divided into high exposure to
oestradiol versus low exposure to oestradiol, by collapsing the
+ days and the no.E days, respectively.
Metaproterenol
Metaproterenol (MP) (Sigma, Israel): a non-selective β -adrenergic
agonist, with a higher affinity to β 2 receptors than to β 1 and a half-
life of about 2 h in rats (Muacevic, 1985). MP was dissolved in
PBS for both s.c. injection and for in vitro use.
Swim stress
A weight of 25 g kg–1 of body weight was attached to the tails of
stressed rats. Each stressed rat was then placed for 3 min in a tank
containing water 35 cm deep at a temperature of 37° C, followed
by a 3 min rest period. This procedure was repeated 5 times
successively. All rats housed in a cage either served as controls or
were stressed. Rats from the control groups were left undisturbed
in the vivarium.
Anti-NKR-P1 mAb
The anti-NKR-P1 (anti-rat NKR-P1A, Pharmingen, USA), origi-
nally termed mAb 3.2.3, binds to a surface antigen (NKR-P1)
expressed on fresh and IL-2 activated NK cells in the rat, and, to a
much lesser degree, on polymorphonuclear cells (Chambers et al,
1992). In vivo treatment of rats with anti-NKR-P1 selectively
depletes large granular lymphocyte (LGL)/NK cells and eliminates
NK and antibody dependent non-MHC-restricted cell cytotoxicity.
T cell function and the percentage of T cells, monocytes, and
PMNs are unaffected (Chambers et al, 1989; van den Brink et al,
1991). Conjugated with FITC, anti-NKR-P1 is used in FACS
analysis to identify NK cells.
Flow cytometry
An aliquot of 100 µ l of blood was combined with 50 µ l of PBS
(supplemented with 2% FCS and 0.1% NaN3) and 0.1 µ g FITC-
conjugated anti-NKR-P1. Samples were kept in the dark at room
temperature thereafter. Following a 15 min incubation period, 2 ml
FACs lysis solution was added (Becton Dickinson), and 10 min
later, samples were centrifuged for 5 min at 500 g and the lysis
solution was aspirated. Cells were washed again with 2 ml PBS
(5 min centrifugation, 300 g) and resuspended in 300 µ l of PBS
for flow cytometry analysis using a FACScan (Becton Dickinson).
The criterion for positive identification of spontaneously active
LGL/NK cell was defined as being above a level of fluorescence
intensity that distinguishes between bright and dim stained
populations of NKR-P1 positive cells, as described previously by
Chambers et al (Chambers et al, 1989, 1992). These previous
studies also demonstrated that NKR-P1 is expressed by 94% of
blood LGL cells and that the NK cytolytic activity was totally
contained in the NKR-P1 bright cell population. Poly-
morphonuclear (PMN) leukocytes were found to express low
levels of NKR-P1 and categorized as dim cells, and macrophages
and mast cells were found to be negative (Chambers et al, 1989).
In our studies, bright cells are defined as showing above 150
relative fluorescence intensity units, a level that distinguished
between the two non-overlapping populations of the dim and
bright NKR-P1+ cells. Nonspecific binding was assessed using
nonspecific IgG1 which consistently yielded 0% of brightly
stained cells.
Whole blood NKA assay
This 4 h cytotoxicity procedure assesses anti-tumour NKA per ml
blood without prior purification of PBMCs (or the exclusion of
any cell population). It reduces the time between blood withdrawal
and assessment of cytotoxicity, and lessens the potential interfer-
ence with NK cell function. Our previous studies (Page et al, 1994;
Ben-Eliyahu et al, 1996) indicate that cytotoxicity in this assay
depends on NK cells, since their selective depletion nullified all
specific killing.
Blood was drawn into a heparinized syringe containing 25 units
ml–1 of blood. Exactly 1 ml of blood was washed once with PBS
(diluted 1:4 volume/volume, centrifuged at 300 g for 10 min, and
supernatant aspirated to original blood volume), and washed twice
with complete media (RPMI 1640 media supplemented with 10%
heat-inactivated FCS, 50 µ g ml–1 gentamicin, 2 mM L-glutamine,
0.1 mM non-essential amino acids, and 1 mM sodium pyruvate).
For each of the 8 effector to target (E:T) ratios used, 100 µ l of
washed blood was placed into each well of a microtitre plate and
150 µ l of 51Cr-labelled YAC-1 tumour cells in complete media
was added on top of the blood. A concentration of 3.2 × 106 ml–1
YAC-1 was used for the lowest E:T ratio (approximately 1:16
NK:YAC-1, depending on individual number of NK cells ml–1 of
blood) and sequentially diluted by two to produce higher E:T
ratios (approximately 8:1 at the highest). Spontaneous (SP) and
maximal (MAX) releases of 51Cr from target cells were determined
by substituting blood with complete media or TRITON X-100
(Sigma, Israel), respectively. Plates were centrifuged at 500 g for
10 min to create a buffy coat layer of leukocytes and target cells on
top of the red blood cells prior to a 4 h incubation period.
Following incubation, plates were again centrifuged and aliquots
of 100 µ l of the supernatant were recovered from each well for
assessment of radioactivity in a γ -counter. SP and MAX release of
radioactivity from tumour cells were measured separately for each
of the 6 tumour concentrations, and percent specific lysis was
calculated for each E:T ratio using the formula (0.8 ×
X SP)/MAX SP) × 100, where X is the experimental release.
The X value is multiplied by 0.8 to correct for the reduction in the
supernatant volume into which 51Cr is released. This reduction is
caused by the presence of RBCs in the wells (MAX and SP
are assessed in the absence of RBCs). The exact E:T ratio were
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cells determined by the FACS analysis. The level of cytotoxicity
for each of the 8 NK:YAC-1 ratio used for statistics and for graph
presentation were calculated using a regression exponential fit
method (Pollock et al, 1990).
Radiolabelling of YAC-1 target cells
40 × 106 cells YAC-1 cells were incubated for 1 h with 200 µ Ci
51Cr (in 200 µ l saline), 400 µ l FCS, and 300 µ l complete media.
Following incubation, cells were washed 3 times (300 g, for 10 min)
and adjusted to the desired concentration in complete media.
MADB106 tumour line
MADB106 is a selected variant cell line obtained from
a pulmonary metastasis of a mammary adenocarcinoma
(MADB100) chemically induced in the inbred F344 rat (Barlozzari
et al, 1985). Following i.v. inoculation, MADB106 tumour cells
seed and colonize only to the lungs, and the number of tumour cells
retained in the lung 24 h following inoculation, as well as the
consequent metastases enumerated weeks later are highly depen-
dent on NK activity (Barlozzari et al, 1985; Ben-Eliyahu and Page,
1992).
The MADB106 cell line was maintained in monolayer cultures
in complete media and separated from the flask using 0.25%
trypsin.
Radiolabelling of MADB106 tumour cells and
assessment of lung tumour retention
For assessment of lung tumour retention, DNA radiolabelling of
tumour cells was accomplished by adding 0.4 mCi ml–1 of
125Iododeoxyuridine (125IDUR) (ICN Radiochemicals, Irvine, CA,
USA) to the growing cell culture one day before harvesting the
cells for injection.
For tumour cell injection, rats were lightly anaesthetized with
halothane, and 4 × 105 kg–1 125IDUR-labelled MADB106 tumour
cells in approximately 0.5 ml of PBS were injected into their tail
vein. 9 h later, rats were euthanized with halothane, and their lungs
removed and placed in a gamma-counter for assessment of
radioactive content. The percentage of tumour cells retained was
calculated as the ratio of radioactivity measured in the lungs to
total radioactivity in the injected tumour cells suspension. Our
previous studies have indicated that the levels of lung radioactivity
reflect the numbers of viable tumour cells in the lungs (for more
information see Ben-Eliyahu & Page, 1992).
Group assignment, counterbalancing and statistics
Rats did not synchronize their oestrous cycle within or between
cages in any of the experiments, as was the case in our previous
studies (Ben-Eliyahu et al, 1996). About half of the rats had a
cycle of 4 days and half of 5 days. Approximately even numbers of
rats were in each of the oestrous phases/days during the day of the
experiment, and the experimenters were naive to the rats’ oestrous
phase. The time and order of MP/saline injection, blood with-
drawal, and tumour injection were counterbalanced across all
groups in all experiments (i.e., conducted in parallel in all groups).
For each experiment, the relevant procedures were completed in
all animals within less than 90 minutes. For statistical analysis,
ANOVA was conducted, and, provided significant group differ-
ences existed, Scheffe or Bonferroni post hoc tests were used to
identify specific differences. α was set to 0.05 in all experiments.
PROCEDURES AND RESULTS
Exp. 1: The effects of MP and the oestrous cycle on
MADB106 lung tumour retention (LTR)
On the day of the experiment, 140 rats at different oestrous phases
were injected s.c. with either saline (control), 0.4 mg kg–1 MP, or
0.8 mg kg–1 MP. One h later, radiolabelled MADB106 cells were
injected i.v. under light halothane anoesthesia. 9 h later rats were
euthanized with halothane and lungs removed for the assessment
of LTR. The experiment was conducted in two replicates, each
using 70 rats representing all experimental groups.
Results
The two replicates yielded a very similar pattern of effects, and
thus were combined. To overcome daily differences in baseline
levels of LTR between the 2 replicates, results from the second
replicate were multiplied by a factor of 2.3, equalizing the average
levels of saline-treated animals in the 2 replicates. Rats were
approximately evenly distributed across the different days of the
oestrous cycle, and categorized as ‘High’ or ‘Low’ for exposure to
oestradiol as described above.
Whereas no significant effects of the oestrous cycle on baseline
levels of LTR were evident, marked effects of the oestrous cycle
were revealed in rats injected with MP. The LTR-increasing effects
of MP were proportional to the duration of exposure to oestradiol
(Figure 1), and were significantly larger during the high oestradiol
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Figure 1 The effects of the β -adrenergic agonist MP, and of the number of
days of pre-exposure to oestradiol along the oestrous cycle, on lung tumour
retention of the MADB106. Number of days of exposure to high levels of
oestradiol prior to MADB106 inoculation is noted +1E, +2E and +3E, and the
number of complete days following the decline of oestradiol is noted 1no. E
and 2no.E (see Methods for details). The line represents levels of oestradiol
in F344 rats one day before the administration of the MADB106 (adopted
from Ben-Eliyahu et al, submitted). Both oestradiol levels and lung tumour
retention reflect the average across the light phase of each dayexposure period compared to the low oestradiol exposure period
(Figure 2). Specifically, two-way ANOVA revealed a significant
main effect for MP (F(2,134) = 16.7, P < 0.05), a significant main
effect for exposure to oestradiol (high vs. low) (F(1,134) = 5.2,
P < 0.05), as well as a significant interaction between these
2 factors (F(2,134)) = 3.4, P < 0.05). Post hoc Scheffe comparison
indicated that in rats injected with 0.8 mg kg–1 MP, LTR was
significantly higher during the high oestradiol period then during
the low oestradiol period (P = 0.01).
Exp. 2: The effects of swim stress and the oestrous
cycle on the number and activity of NK cells
On the day of the experiment, 44 rats were exposed to swim stress,
and 27 rats remained undisturbed in their home cages. Two hours
following stress, 1.5–2 ml blood was simultaneously drawn from
the stressed and control rats. Blood was drawn by cardiac puncture
under light halothane anaesthesia using a 25 G needle. The number
of NK cells per ml of blood and activity per NK cells were
assessed thereafter in all 71 rats, as described above.
Results
Of the 71 rats, 41 were categorized as ‘high’ exposure to oestradiol
(26 were stressed and 15 were control), and 30 were categorized as
‘low’ exposure to oestradiol (18 were stressed and 12 were
control). Repeated measure ANOVA (for the 8 E:T ratio) indicated
that swim stress significantly suppressed NK activity per NK cells
in the high oestradiol group (F(1,273) = 6.4, P < 0.05), whereas no
effect of swim stress was evident in the low oestradiol group
(F(1,196) = 0.24, P = 0.65) (Figure 3). A 2 × 2 repeated measure
ANOVA indicated a significant interaction between the effects of
stress and exposure to oestradiol (F(1,469) = 3.93, P < 0.05). No
significant oestrous cycle effects on baseline levels of NKA were
evident. The numbers of NK cells were not significantly affected
by swim stress or by the oestrous cycle, nor was there an interac-
tive effect between these two factors.
Exp. 3: The in vitro effects of MP and of the oestrous
cycle on NKA
On the day of the experiment, 5–8 ml blood was drawn by cardiac
puncture under halothane anaesthesia from 35 rats at different
oestrous phases, and serum was replaced with complete media as
described in the procedure for assessing NKA. Different doses of
MP (to achieve final concentrations of 1 × 10–7, 3 × 10–7, 1 × 10–8,
3 × 10–8, or 1 × 10–9 M in the NK assay) were added to different
aliquots of 1 ml blood from each rat. Two additional aliquots from
each rat were used as control and were supplemented with vehicle.
One h later, NKA was assessed as described above, without
additional ‘washing’ of the blood. The experiment was conducted
in two replicates, using 12 and 24 rats.
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Figure 2 The effects of the β -adrenergic agonist MP, and of the oestrous
cycle, on lung tumour retention of the MADB106. The oestrous cycle was
divided into days of prior exposure to high levels of oestradiol, diestrus-3,
proestrus and oestrus (D3, pro, oestrus), versus days of prior low levels of
oestradiol, dioestrus-1 and dioestrus-2 (D1 and D2). The effects of MP were
markedly larger during the high oestradiol period compared to the low
oestradiol period, as indicated by a significant interaction between the effects
of MP and of the oestrous cycle. No effect of the oestrous cycle was evident
in the absence of MP (Control)
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Figure 4 The effects of the oestrous cycle and in vitro exposure to the
β -adrenergic agonist, MP, on NKA. NKA is presented as % of control
(LUMP/LUcontrol). The oestrous cycle was divided into days of prior
exposure to high levels of oestradiol, diestrus-3, proestrus and oestrus (D3,
pro, oestrus), versus days of prior low levels of oestradiol, diestrus-1 and
diestrus-2 (D1 and D2). The in vitro effects of MP were markedly larger if
blood was drawn during the high oestradiol period compared to the low
oestradiol. Significant suppression of NKA was evident in the 4 higher doses
of MP in the high oestradiol condition, but only in the highest dose of MP in
the low oestradiol condition. No effect of the oestrous cycle was evident in
the absence of MP (not shown in the figure)Results
Of the 36 rats, 22 were categorized as ‘high’ and 14 as ‘low’ for
exposure to oestradiol. To compare NKA between the different
doses of MP, lytic units (LU) were calculated for each rat using the
formula 100/ET1/3, where ET1/3 is the E:T ratio needed to reach a
1/3 increment in target cytotoxicity (along the different E:T ratios)
in the aliquots of blood not exposed to MP (average of both repli-
cates). The regression exponential fit method (Pollock et al, 1990)
was used to infer ET1/3 from the data. Data were converted to a
percentage of control levels in each rat, maintaining the 2 repli-
cates of 0 levels of MP as 2 different numbers to indicate assay
errors. Whereas in the high group, MP significantly suppressed
NKA in a dose-dependent manner beginning from the second
dose, in the Low group only the highest dose of MP had a signifi-
cant effect (Figure 4). ANOVA indicated significant main effects
of MP dose (F(5,195) = 13.3, P < 0.05) and of exposure to oestra-
diol (F(1,195) = 4.9, P < 0.05), and Bonferroni post hoc compar-
ison (α corrected to 0.00511 for the 10 comparisons) indicated
significantly lower NKA in the 4 higher doses in the High
estradiol condition, but only in the highest dose of MP in the Low
estradiol condition. Baseline levels of NKA (no MP) along the
oestrous cycle did not show significant differences.
DISCUSSION
As in our previous studies, β -adrenoceptor stimulation and stress
suppressed NKA and host resistance to metastasis. The main
finding of the current study is that this suppression was markedly
modulated by the oestrous cycle. Specifically, on days diestrus-3,
proestrus, and oestrus, the metastasis-enhancing effects of the 
β -adrenergic agonist, metaproterenol (MP), were significantly
greater than on days diestrus-1 (metoestrus) and diestrus-2.
Similarly, swim stress suppressed NKA only during this 3-day
period, and markedly lower concentrations of MP were sufficient
to suppress NKA in vitro if blood was drawn during these 3 days.
On the other hand, when rats were not stressed or not challenged
with MP, the oestrous cycle had no effect on NKA or levels of
resistance to metastasis.
Because we hypothesized that the effects of the oestrous cycle
would be restricted to conditions of adrenoceptor stimulation, we
made a deliberate effort to minimize procedural stress in the
control groups. Additionally, in order to avoid unplanned exposure
of leukocytes to catecholamines secreted upon blood withdrawal,
plasma was rapidly replaced by an artificial medium (see
Methods). Such measures were not taken in previous studies, in
which we and others found oestrous cycle effects on NKA and
resistance to metastasis without deliberately exposing rats to stress
hormones (White et al, 1982, 1997; Sulke et al, 1985; Ratajczak et
al, 1988; Ben-Eliyahu et al, 1996; Page and Ben-Eliyahu, 1997).
Based on the findings of the current study, in which the effects of
the oestrous cycle are shown to be limited to conditions of stress or
adrenoceptor stimulation, we suggest that the previous findings
are attributable to unintended procedural stress and the systemic
release of catecholamines.
The in vitro study, in which MP was added to blood drawn at
different oestrous phases, directly and clearly indicates that the
suppression of NKA by β -adrenergic stimulation is modulated by
the oestrous cycle. We have conducted the same study in women
and found homologous findings. Specifically, 3-fold higher
concentrations of MP were needed to achieve the same levels of
NK suppression in blood drawn during the follicular phase
compared to blood drawn during the luteal phase (Shakhar et al,
2000). In other studies, the luteal phase has been reported to be
characterized by a higher lymphocyte expression of β 2-adrenocep-
tors, and by a higher cAMP response to isoprenaline (Wheeldon et
al, 1994). Suppression of NKA by adrenergic agonists, as well as
by other immunomodulators (e.g. prostaglandin-E2), is known to
be mediated by elevated cAMP (Whalen and Bankhurst, 1990).
Therefore, we suggest that alterations in the expression of β -
adrenoceptors and their functional response, underlie the modula-
tory effects of the ovulatory cycle on the suppression of NKA by
β -adrenergic agents in human and murine NK cells.
The in vivo study indicated that the oestrus cycle modulates
resistance to metastasis under the condition of β -adrenoceptor
activation. We propose that this effect is mediated by oestrous
modulation of the suppressive effects of MP on NK activity.
Firstly, the MADB106 line is highly sensitive to NKA in vivo.
Specifically, selective depletion of NK cells causes an approxi-
mately 200-fold increase in MADB106 lung tumour retention and
the number of lung metastases (Ben-Eliyahu et al, 1991; Ben-
Eliyahu and Page, 1992; Shakhar and Ben-Eliyahu, 1998).
Secondly, we have recently reported various findings indicating
that the increase in MADB106 metastasis caused by the adminis-
tration of MP, with the same timing and dosage used here, is medi-
ated by suppression of NKA. For example, selective depletion of
NK cells prevented the metastasis-enhancing effects of MP
(without causing a ceiling effect) (Shakhar and Ben-Eliyahu,
1998). Therefore, the modulatory effects of the oestrous cycle on
the metastasis-enhancing effects of MP, are likely to be mediated
by oestrus modulation of adrenergic suppression of NKA. Such
modulation of NKA was indeed demonstrated in vitro in the
current study in rats, and in our corresponding study in women
(Shakhar et al, 2000).
The swim stress paradigm was chosen because it reliably
suppresses NKA per NK cell and consequently increases metas-
tasis of the MADB106 line (Ben-Eliyahu et al, 1991, 1999, in
press). This paradigm is known to induce the release of both
glucocorticoids and catecholamines. However, the metastasis-
enhancing effects of this paradigm, as well as several other stress
paradigms, are mediated by catecholamines rather than glucocorti-
coids (Ben-Eliyahu et al, in press). We have also shown that
administration of adrenaline or MP in rats suppresses NKA, and
that the NK suppressive effects of this stress paradigm are medi-
ated by the release of adrenal catecholamines (Shakhar and Ben-
Eliyahu, 1998; Ben-Eliyahu et al, in press). Therefore, we suggest
that the current NK suppressive effects of swim stress, which are
modulated by the oestrous cycle in female F344 rats, are also
mediated by the systemic release of catecholamines. In this exper-
iment, we used a stress paradigm, rather than a systemic injection
of MP, in order to make our finding pertinent to the more complex
stress-induced changes in the physiological milieu. In order to
further simulate the clinical situation and to assess the role of
adrenergic and other mechanisms in mediating the effects of
surgery, our ongoing studies employ spontaneously metastasizing
tumours and their surgical excision.
Several lines of evidence suggest that oestradiol is a prominent
hormonal mediator of the current effects of the oestrous cycle,
and that its impacts are manifested approximately one day
following its increase, and terminate one day after its decline (a
delay which also characterizes other effects of oestradiol). Firstly,
as seen in Figure 1, the susceptibility to metastasis parallels serum
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have recently conducted a comprehensive study of the levels of
sex hormones along the oestrous cycle in the F344 rat, and found
that no other sex hormone is synchronized with the susceptibility
to metastasis as closely as oestradiol (Ben-Eliyahu et al,
submitted). Specifically, progesterone has two distinct peaks of
similar size along the oestrous cycle, and LH, FSH, prolactin,
testosterone, and corticosterone levels begin their increase on
proestrus day, after susceptibility to metastasis has already
increased. Secondly, in a previous study, we have shown that the
infusion of physiological levels of oestradiol, but not proges-
terone, to ovariectomized F344 females, increased susceptibility
to MADB106 metastasis. This effect was evident only 24 h after
the infusion of oestradiol (Ben-Eliyahu et al, 1996), as was also
the case in the current study in which the effects were evident
only 24 h after the rise in oestradiol levels. Thirdly, expression of
β -adrenergic receptors on women’s lymphocytes was found to be
higher during days of elevated oestradiol levels (days 21–23 vs.
days 2–4) (Wheeldon et al, 1994), although in humans this period
is also characterized by high levels of progesterone. Lastly, our
corresponding findings in women indicate that the in vitro
suppressive effects of MP on NKA were better correlated with
levels of oestradiol than with levels of progesterone (Shakhar et
al, 2000). Nevertheless, direct evidence is required to confirm the
role of oestradiol and to assess the potential contribution of other
hormones.
It is interesting to assess the relevance of our findings to the
clinical phenomenon. In clinical settings, specific periods of the
menstrual cycle during which breast cancer was surgically
removed, have been associated with a higher risk of metastasis and
mortality (Lemon and Rodriguez-Sierra, 1996). Our studies in rats
are limited to a single (although important) immune function
controlling metastasis, one mammary tumour line, and the
response to adrenergic challenge. Unfortunately, the timing of the
increased impact of adrenergic agents indicated by our animal and
human studies (during and shortly after exposure to oestradiol),
cannot be easily compared to the timing of the high-risk period
observed clinically, as different clinical reports suggest different
menstrual phases as being the high-risk period (Lemon and
Rodriguez-Sierra, 1996). However, the apparent inconsistency
within the clinical literature, and the lack of an exact time concur-
rence between our findings and the clinical observations, do not
create a major difficulty in relating our findings to the clinical
phenomenon, as both apparent inconsistencies may be the result of
hospital variation in perioperative routines. For example, it may be
suggested that the biopsy itself and the stress it induces promotes
the dissemination of the tumour, more so when radical biopsy is
conducted. Different hospitals may employ different methods of
biopsy and conduct them at a uniform but different time intervals
before surgery. Therefore, given our finding in rats and humans,
we propose the following mechanism as underlying, at least partly,
the clinical observation. Surgery itself (or a radical biopsy)
promotes the metastatic process, while certain aspects of the
menstrual cycle (e.g., levels of specific sex hormones) modulate
the patient’s resistance to metastasis in these vulnerable condi-
tions. Specifically, we suggest that a mechanism contributing to
the promotion of metastasis by surgery is an adrenergic suppres-
sion of NK activity. Indeed, suppression of NKA is well docu-
mented clinically following surgery (Pollock et al, 1992; Beitsch
et al, 1994; Shirakawa et al, 1998), has been suggested by animal
and human studies to promote metastasis (Brittenden et al, 1996;
Ben-Eliyahu et al, 1999), and is shown here and in our study in
women to be modulated by the oestrous and menstrual cycles.
A possible implication of the present findings and our interpre-
tations, is that the prevention of adrenergically-mediated immune
suppression would reduce the need to control the timing of surgery
in premenopausal women. Since adrenergic suppression of
immune competence is probably not restricted to the surgical
effects of operating on breast cancer patients, limiting the immune
suppression induced by surgery may benefit all patients under-
going intrusive procedures while bearing metastasizing tumours.
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